Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cerus Corporation    CERS

CERUS CORPORATION (CERS)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/11/2018 07/12/2018 07/13/2018 07/16/2018 07/17/2018 Date
6.99(c) 7.42(c) 7.27(c) 7.32(c) 7.41(c) Last
432 338 1 969 281 771 318 544 396 428 996 Volume
-0.99% +6.15% -2.02% +0.69% +1.23% Change
More quotes
Financials (USD)
Sales 2018 71,4 M
EBIT 2018 -52,3 M
Net income 2018 -54,5 M
Finance 2018 43,1 M
Yield 2018 -
Sales 2019 102 M
EBIT 2019 -42,1 M
Net income 2019 -44,1 M
Finance 2019 8,71 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 12,7x
EV / Sales2019 9,22x
Capitalization 949 M
More Financials
Company
Cerus Corp. engages in the research, development, and manufacture of biomedical and surgical products.It produces blood system for platelets and plasma.It markets its products under the INTERCEPT brand.The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is... 
More about the company
Surperformance© ratings of Cerus Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CERUS CORPORATION
07/10CERUS : New Navy Policy Implements Full Adoption of Pathogen-Reduced Apheresis P..
BU
06/28Free Technical Reports on Cerus and Three Additional Biotech Equities
AC
06/25CERUS CORPORATION : Sees Product Demand Double, Revises Guidance Upward
AC
06/15CERUS : Presents Results of European Phase 3 Chronic Anemia Study at the 23rd Co..
BU
06/14CERUS : Announces Presentations Highlighting INTERCEPT Blood Systems at the 35th..
AQ
06/07CERUS CORP : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/05CERUS : Baylor St. Luke's Medical Center First in Country to Enroll Patients in ..
AQ
06/01CERUS : Announces Presentations Highlighting INTERCEPT Blood Systems at the 35th..
BU
05/25CERUS : Announces Additional BARDA Funding to Support Development of INTERCEPT B..
AQ
05/18CERUS : Announces Additional BARDA Funding to Support Development of INTERCEPT B..
AQ
More news
Sector news : Medical Devices & Implants
07/17BAXTER INTERNATIONAL : Releases FDA Warning Letter for 2017 Inspection in India
DJ
07/11Brazil prosecutors allege jailed GE executive helped company partake in medic..
RE
07/11MEDTRONIC : Gets FDA Approval for Less-Invasive Heart Pump Implant Procedure
DJ
07/09BECTON DICKINSON AND : Completes Acquisition of TVA Medical
DJ
06/29ESSILOR INTERNATIONAL : Luxottica, Essilor extend deadline for merger pending Ch..
RE
More sector news : Medical Devices & Implants
Latest Tweets
07/12VOLUME RADAR ALERT: $CERS CERUS ? TradeIdeas via  
07/11$CERS Cerus - 4/A (Amended Statement of Changes in Beneficial Ownership) SEC .. 
07/10$CERS Cerus - New Navy Policy Implements Full Adoption of Pathogen-Reduced Ap.. 
06/28Want the latest analyst ratings on $CERS $EVC $FFKT $CIFS $FELE? Get Them Del.. 
06/28Report: Developing Opportunities within Torchmark, Cerus, American Equity Inv.. 
More tweets
Qtime:109
News from SeekingAlpha
05/16Cerus nabs $15M government contract 
05/09HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (05/09/2018) 
05/08Cerus' (CERS) CEO Obi Greenman on Q1 2018 Results - Earnings Call Transcript 
05/08Cerus beats by $0.01, misses on revenue 
05/07Notable earnings after Tuesday?s close 
Chart CERUS CORPORATION
Duration : Period :
Cerus Corporation Technical Analysis Chart | CERS | US1570851014 | 4-Traders
Technical analysis trends CERUS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 7,50 $
Spread / Average Target 2,5%
EPS Revisions
Managers
NameTitle
William Mariner Greenman President, Chief Executive Officer & Director
Daniel N. Swisher Chairman
Suzanne Margerum Vice President-Manufacturing & Operations
Kevin Dennis Green Chief Financial Officer & Vice President-Finance
Laurence M. Corash Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
CERUS CORPORATION119.23%949
STRYKER CORPORATION12.57%65 138
SMITH & NEPHEW3.42%15 564
WRIGHT MEDICAL GROUP NV14.77%2 700
JAPAN LIFELINE CO., LTD.23.09%2 384
GLAUKOS CORP61.75%1 471